Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice

Area of Science:

• Cardiology
• Endocrinology
• Molecular Medicine

Background:

• Diabetic cardiomyopathy (DCM) involves heart dysfunction in diabetes mellitus, independent of other heart diseases.
• It progresses from subtle changes to fibrosis, diastolic dysfunction, and heart failure.
• Current treatments are limited, with sodium-glucose transport protein 2 inhibitors and bariatric surgery being exceptions.

Purpose of the Study:

• To review emerging treatments for diabetic cardiomyopathy.
• To highlight therapies targeting specific molecular mechanisms of DCM.
• To present evidence from preclinical and clinical studies.

Main Methods:

• Literature review of preclinical studies and clinical trials.
• Focus on emerging therapeutic strategies for DCM.
• Analysis of molecular targets and their therapeutic implications.

Main Results:

• DCM involves complex molecular pathways including nutrient sensing, autophagy, mitochondrial function, oxidative stress, inflammation, and fibrosis.
• Emerging treatments aim to address these specific molecular dysfunctions.
• Evidence from studies suggests potential efficacy of these novel approaches.

Conclusions:

• Diabetic cardiomyopathy is a distinct entity with multifaceted molecular underpinnings.
• Targeting these specific molecular mechanisms offers a promising avenue for novel DCM therapies.
• Further clinical investigation is warranted to validate these emerging treatments.